Stem cell engineering towards the optimization of the ex-vivo expansion of human hematopoietic stem/progenitor cells for cellular therapies

Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S60
Author(s):  
C.L. da Silva ◽  
P.Z. Andrade ◽  
A.M. Soure ◽  
F. Dos Santos ◽  
G. Almeida-Porada ◽  
...  
Blood ◽  
2011 ◽  
Vol 117 (23) ◽  
pp. 6083-6090 ◽  
Author(s):  
Ann Dahlberg ◽  
Colleen Delaney ◽  
Irwin D. Bernstein

AbstractDespite progress in our understanding of the growth factors that support the progressive maturation of the various cell lineages of the hematopoietic system, less is known about factors that govern the self-renewal of hematopoietic stem and progenitor cells (HSPCs), and our ability to expand human HSPC numbers ex vivo remains limited. Interest in stem cell expansion has been heightened by the increasing importance of HSCs in the treatment of both malignant and nonmalignant diseases, as well as their use in gene therapy. To date, most attempts to ex vivo expand HSPCs have used hematopoietic growth factors but have not achieved clinically relevant effects. More recent approaches, including our studies in which activation of the Notch signaling pathway has enabled a clinically relevant ex vivo expansion of HSPCs, have led to renewed interest in this arena. Here we briefly review early attempts at ex vivo expansion by cytokine stimulation followed by an examination of our studies investigating the role of Notch signaling in HSPC self-renewal. We will also review other recently developed approaches for ex vivo expansion, primarily focused on the more extensively studied cord blood–derived stem cell. Finally, we discuss some of the challenges still facing this field.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1174-1174
Author(s):  
Taito Nishino ◽  
Atsushi Iwama

Abstract Abstract 1174 Ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs) have recently been explored to optimize autologous and allogeneic HSPC transplantation and shown to be effective in the field of stem cell biology. However, to our knowledge, identification of culture conditions that allow HSPCs expansion and long-term hematopoietic reconstitution have remained incomplete, and clinical methods to expand human HSPCs have yet to be realized. In this study, we assumed that some small molecule compounds may preferentially activate signals that are required for optimal HSPC expansion and facilitate self-renewal of hematopoietic stem cells (HSCs). Thus, we evaluated the effects of several biologically active compounds on the ex vivo expansion of CD34+ hematopoietic stem and progenitor cells from human cord blood (hCB) and identified Garcinol, a plant-derived natural product as a novel modulator of HSPC proliferation. We cultured hCB CD34+ cells in serum-free medium supplemented with human thrombopoietin, human stem cell factor and Garcinol for 7 days and analyzed the cellular phenotype of the cultured cells by flow cytometry and colony assay. Although the total number of cells cultured with Garcinol was similar to those cultured without Garcinol, the cultures with Garcinol showed >2-fold increase in the number of CD34+CD38- hematopoietic stem and progenitor cells and contained 2-fold more high-proliferative-potential colony-forming cells (HPP-CFCs; >1mm in diameter) compared to control cultures. Correspondingly, SCID-repopulating cells (SRCs) were increased 2-fold during a 7-day culture with Garcinol compared to cultures without Garcinol. These findings suggest that Garcinol efficiently promotes the net expansion of HPSCs. To investigate the structure-activity relationship of Garcinol, we synthesized the chemical derivatives of Garcinol and evaluated the effect of Garcinol and its derivatives, Isogarcinol and O, O'-dimethylisogarcinol, on the proliferation of CD34+CD38- cells. Although Isogarcinol exhibited almost the same activity as Garcinol, O, O'-dimethyl isogarcinol was scarcely effective in the CD34+CD38- cell proliferation. Correspondingly, O, O'-dimethylisogarcinol had no effect on numbers of HPP-CFCs. These results indicate that dihydroxybenzoyl moiety is crucial for the positive effect of Gacinol on HSPCs.Garcinol has been reported to be a potent inhibitor of histone acetyltransferases (HAT). Thus, we estimated the HAT activity in cells treated with Garcinol and its derivatives. Garcinol and Isogarcinol inhibited HAT activity while O, O'-dimethylisogarcinol showed much less HAT inhibitory activity as compared to Garcinol and Isogarcinol, which suggested that HAT inhibitory activity of Garcinol is correlate with the expansion of HPSCs. We are now investigating gene expression profiling in cells cultured with Garcinol using DNA microarray analysis and Q-PCR. In conclusion, we have identified Garcinol, a plant-derived small-molecule compound, which exhibits inhibitory effect on HAT activity, as a novel stimulator of HSPC expansion. The results reported here indicate that Garcinol would be applied as a useful tool for the development of novel and efficient technologies for hematopoietic stem cell and gene therapies. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 340-340
Author(s):  
Alla Dolnikov ◽  
Tiffany Holmes ◽  
Tracey A. O’Brien

Abstract Rapid availability of an HLA matched marrow donor for allogeneic hematopoietic stem cell transplantation remains a challenge in the clinical setting and has resulted in increased use of alternate stem cell sources, particularly unrelated umbilical cord blood (UCB). Although UCB transplantation has been used to treat a multiplicity of malignant and non-malignant hematological diseases, success has been limited particularly in adult recipients, because of reduced numbers of stem/progenitor cells in a cord unit resulting in higher graft failure rates, delayed hematopoietic reconstitution and increased transplant related mortality when compared to BM or PBSCs. This has prompted investigation of alternate strategies including multi-unit infusions and ex-vivo expansion systems. Clinical trials incorporating cytokine-based HSC ex-vivo expansion have failed to demonstrate significant shortening of hematologic recovery despite substantial increases in cell dose, suggesting loss of HSC function. Activation of Wnt signaling has previously been shown to maintain HSC function; as such we hypothesized that use of a specific inhibitor of glycogen synthase kinase (GSK-3β) to activate Wnt signaling in combination with cytokine (Flt3L, SCF, TPO) based ex-vivo HSC expansion would result in expansion, maintenance of HSC function and ultimately improve hematological recovery. UCB CD34+ cells were treated with a potent GSK-3β inhibitor; 6-bromoindirubin-3′-oxime (BIO), a synthetic cell-permeable derivative of a natural product, indirubin-3′-oxime, isolated from the molusk Tyrian purple. UCB CD 34+ cells treated with BIO exhibited increased expression of β-catenin that re-located from the cytoplasm to the nuclei to activate transcription of Wnt targets including cyclin D1, c-myc, and HoxB4. When compared to control cells (cytokine only); BIO treated cells demonstrated an increase in the absolute number of nucleated, CD34+ and clonogenic cell numbers in 5–7 day expansion cultures with the best expansion observed at 0.1 μM of BIO. Increased cell cycling, reduced apoptosis and up-regulation of the cell cycle inhibitor p21Waf1 previously shown to maintain HSC function in-vivo was demonstrated in BIO treated cells. Furthermore, BIO significantly improved the hematopoietic supporting ability of murine bone marrow stroma MS5 cells. Increased expansion of myeloid, megakaryocytic and B-cell progenitor cells were all observed. Using a NOD/SCID mouse model we have demonstrated both preservation of function and expansion with increased numbers of engrafting BIO treated human CD34+ UCB (120-fold expansion) compared to control cells (45-fold expansion). The increased expansion of human NOD/SCID repopulating cells suggests improved maintenance of stem cell function during ex-vivo expansion of UCB in the presence of BIO. Activation of the Wnt pathway, through GSK-3β inhibition, is a promising strategy to facilitate expansion and maintain function of UCB HSCs and may overcome current limitations of UCB and allow for greater application of this stem cell source.


2001 ◽  
Vol 285 (4) ◽  
pp. 891-896 ◽  
Author(s):  
Michiko Muramatsu ◽  
Yutaka Hanazono ◽  
Yoji Ogasawara ◽  
Takashi Okada ◽  
Hiroaki Mizukami ◽  
...  

2006 ◽  
Vol 28 (5) ◽  
pp. 335-340 ◽  
Author(s):  
Raquel Gonçalves ◽  
Cláudia Lobato da Silva ◽  
Bruno S. Ferreira ◽  
Maria Amélia N. D. A. Lemos ◽  
Francisco Lemos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document